Search Results

Laser Fusion Startup Xcimer Receives Up to $30.5 Million in Milestone-Based Funding from U.S. Department of Energy

U.S. excimer laser inertial confinement fusion company Xcimer Energy recently announced that it has reached an agreement with the U.S. Department of Energy (DOE) to receive up to $30.5 million in funding support through the DOE's Milestone-based Fusion Development Program. The funds will be disbursed in installments based on the progress achieved toward predetermined R&D milestones. Previously, in June 2026, the U.S. Department of Energy formally approved the preliminary conceptual design and technology development roadmap milestones for Xcimer's fusion power plant architecture, Athena. The Athena architecture is specifically designed for continuous operation, industrial-scale capacity, and a self-sustaining fuel cycle...

2026-10-08

Russia's Kurchatov Institute to Receive 5.7 Billion Rubles in Fiscal Budget Support: Focusing on Controlled Thermonuclear Fusion and Advanced Plasma Technology R&D

The National Research Centre "Kurchatov Institute" will receive approximately 5.7 billion Rubles in dedicated funding support from the Russian federal budget during the period from 2027 to 2029. This fiscal allocation will be specifically used to advance key technology breakthroughs in Controlled Thermonuclear Fusion, as well as the R&D and experimental validation of innovative Plasma Technologies. The above funding plan is explicitly stated in the draft explanatory document of the 2027–2029 federal budget bill published in the electronic database of the Russian State Duma...

2026-10-03

Department of Nuclear Medicine at Peking University First Hospital Receives EARL Theranostics Advanced-L2 Certification, Bringing Theranostics in Line with International Standards

The Department of Nuclear Medicine at Peking University First Hospital has recently officially received the Theranostics Advanced-L2 certification issued by EARL (EANM Research Ltd.), an affiliate of the European Association of Nuclear Medicine, becoming one of the few nuclear medicine theranostics centers in China to obtain this high-level certification. The certification audit standards are rigorous, covering comprehensive dimensions including PET/CT quantitative accuracy, therapy center operations, patient safety management, and clinical competency. Passing the certification means that the department's quantitative imaging and targeted therapy data meet internationally mutually recognized standards and can achieve high-level alignment with advanced nuclear medicine centers in Europe and the United States. During the certification review, EANM President-Elect Professor Felix M. Mottaghy and Ms. Iva...

2026-10-03

Microstructure Imaging's MICSI-PET Software Receives FDA Clearance to Enhance Neurological PET Imaging Using MRI

Microstructure Imaging's software platform has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The platform is designed to enhance neurological positron emission tomography (PET) images using structural magnetic resonance imaging (MRI). The software, called MICSI-PET, can denoise and super-resolve PET images using MRI guidance while preserving quantitative PET information. It supports PET exams for amyloid, Tau, and FDG (fluorodeoxyglucose), and can provide automated Centiloid measurements for amyloid imaging and CenTauR measurements for Tau imaging....

2026-09-18

Holtec SMR project receives regulatory approval to proceed with early site construction

The U.S. Nuclear Regulatory Commission (NRC) has granted Holtec International a regulatory exemption allowing the company to advance certain early construction activities for two small modular reactor (SMR) units at the Palisades Energy Center in Michigan before obtaining a Limited Work Authorization (LWA). Palisades SMR, a wholly owned subsidiary of Holtec International, submitted the first part of a phased construction permit application to the NRC last December for the dual-unit SMR-300 project (Units Pioneer 1 and 2). The application included a request for a Limited Work Authorization to allow construction activities to begin before a construction permit or combined...

2026-09-17

GE HealthCare's StarGuide GX Digital 4D CZT SPECT/CT Receives FDA 510(k) Clearance in the U.S.

GE HealthCare recently announced that its new digital 4D CZT SPECT/CT system, StarGuide GX, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system had previously obtained CE marking, and this U.S. clearance marks progress in the clinical adoption of its next-generation molecular imaging technology. Designed for theragnostics and precision medicine needs, StarGuide GX is a comprehensive SPECT/CT system. It supports imaging at multiple energy levels, enables general-purpose SPECT imaging, and is tailored for emerging tracer applications, including investigational α-emitters, aiming to provide imaging support for clinicians and researchers exploring new pathways in diagnosis, treatment planning, and therapeutic response monitoring.

2026-09-09

Sweden receives sixth state aid application for new nuclear power

The Swedish government has recently received its sixth state aid application for the construction of new nuclear reactors. Swedish Minister for Financial Markets Niklas Wykman stated that Nordic energy company Fortum's establishment of a project company in Sweden to advance new nuclear reactor plans demonstrates that Sweden's current state aid model has been carefully designed to accommodate project development needs. The application was submitted by NuCore Energi, a newly established project company under Fortum, with the project site located at Ävrö near the Oskarshamn nuclear power plant. Wykman has previously expressed repeated support for expanding nuclear energy in Sweden, believing that new nuclear power is of significant importance for long-term economic stability, industrial competitiveness, and climate goals.

2026-09-07

Russia says it has not yet received an invitation for negotiations on Hungary's Paks II nuclear power plant

On September 2, Alexey Likhachev, CEO of Russia's State Atomic Energy Corporation (Rosatom), said during the Eastern Economic Forum in Vladivostok that Rosatom has not yet received an invitation from the Hungarian government for negotiations on the construction project of the Paks II nuclear power plant. Likhachev stated that Rosatom has expressed its willingness to participate in discussions on project parameters in any civilized manner. He noted that the company has always placed the interests of its partners and clients in a position of priority and is prepared to provide explanations and justifications regarding the effectiveness of the project's technical solutions as well as related financial and economic impacts...

2026-09-03

Unit 4 of Japan's Genkai Nuclear Power Plant Receives 72 New Fuel Assemblies

Kyushu Electric Power Co. announced on September 1, 2026, that Unit 4 of the Genkai Nuclear Power Plant has completed the receipt of a batch of new fuel. The new fuel was processed and shipped by Mitsubishi Nuclear Fuel Co., Ltd., with transportation carried out from August 27 to September 1, 2026. According to Kyushu Electric Power, the new fuel delivered to Unit 4 of the Genkai Nuclear Power Plant consists of 72 fuel assemblies, transported in 36 shipping containers via both land and sea routes. Two control rod assemblies were also transported along with this batch of fuel. Fuel used in nuclear power plants...

2026-09-02

GE HealthCare's Photonova Spectra Photon-Counting CT Receives CE Mark, to Be Commercialized in Countries Recognizing CE Marking

On August 31, GE HealthCare announced that its advanced photon-counting computed tomography (PCCT) system, Photonova Spectra, has received CE marking. The system utilizes GE HealthCare's proprietary Deep Silicon™ detector technology. This certification will expand the system's availability in countries and regions that recognize the CE mark and pave the way for its clinical use. According to reports, Photonova Spectra is designed to address the growing patient volumes and increasing diagnostic complexity faced by healthcare institutions today, aiming to provide clinicians with clearer and more timely imaging information. Leveraging deep silicon detector technology, the system can acquire spectral and spatial imaging information in each scan...

2026-09-01

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

German Photon and Neutron Research Data Alliance Receives €8.3 Million in Second-Phase Funding

The German National Research Data Infrastructure consortium for photon and neutron experimental data (DAPHNE4NFDI) will enter its second funding phase, receiving initial funding of €8.3 million, with the funding period running until the end of 2028. Since 2021, the consortium has been working to improve the management of research data from photon and neutron experiments, making the data easier to find, access, and reuse over the long term. DAPHNE4NFDI is one of the disciplinary consortia under the German National Research Data Infrastructure (NFDI), with members including the German Electron Synchrotron (DESY), Kiel University (CAU), and other universities and research institutions. The funding decision is based on a recommendation from the German Research Foundation (DFG). Since January 2026...

2026-08-31

Japan's Tokai No. 2 Nuclear Power Plant Seawall Reinforcement Plan Receives Basic Approval

Japan's Nuclear Regulation Authority (NRA) held a review meeting on the 27th local time and basically approved the seawall structural modification plan for the Tokai No. 2 Nuclear Power Plant submitted by Japan Atomic Power Company (JAPC). The plant is located in Tokai Village, Ibaraki Prefecture, Japan, and the relevant seawall is an important component of the safety measures required for restart, with foundation defects having been discovered during construction. According to JAPC's explanation, the modification plan does not remove the underground foundation where defects were found, but instead adds pile foundations around it and uses cement-based materials to reinforce the ground. Regarding this plan, JAPC submitted an assessment of the seawall's seismic and tsunami resistance performance after modification, concluding that the structurally adjusted seawall can still fulfill the functions required of a tsunami protection facility.

2026-08-28

Canadian Light Source Synchrotron at University of Saskatchewan Receives $3 Million CAD in Upgrade Funding

On August 26, Innovation Saskatchewan announced that it will provide $3 million CAD in funding to the Canadian Light Source synchrotron at the University of Saskatchewan to support the installation of an advanced solid-state amplifier, advancing the facility's upgrade efforts. According to reports, this solid-state amplifier is a key component of the Canadian Light Source's core particle accelerator and will support the operation of its 22 synchrotron radiation beamlines. The upgrade is expected to enhance facility performance, operational reliability, and energy efficiency, further strengthening its capacity for cutting-edge scientific research. The Canadian Light Source is Canada's only synchrotron facility. Synchrotrons use electromagnetic fields and radiofrequency waves to accelerate electrons to near the speed of light, keeping them in a circular orbit; as electrons move, they generate high-brightness, highly focused synchrotron radiation beams, which are directed to different experimental beamlines to help researchers study material structures and properties at the atomic scale.

2026-08-27

France's n-Floating Floating Nuclear Power Project Receives Nearly One Million Euros in Funding

newcleo announced on August 26 that a consortium led by the company has been selected for a call for projects managed by Bpifrance, the French public investment bank, supporting the decarbonization of France's maritime sector. The consortium will advance research on a floating nuclear power solution called n-Floating, with the project receiving nearly one million euros in funding and an expected duration of approximately 18 months. The n-Floating project aims to validate the relevance and technical feasibility of a new floating nuclear power solution. Under the proposed concept, a non-self-propelled floating unit would carry multiple LFR-AS-200 reactors, each with an electrical output of 200 megawatts. LFR-AS-200 is one of the lead-cooled fast reactor technology lines developed by newcleo.

2026-08-27